Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Longitudinal MRI contrast enhanced monitoring of early tumour development with manganese chloride (MnCl2) and superparamagnetic iron oxide nanoparticles (SPIOs) in a CT1258 based in vivo model of prostate cancer

Figure 2

7T MRI of a male NOD-scid mouse after subcutaneous injection of 10 4 MnCl 2 labelled CT1258 cells. The MRI scans were performed on the same day as the injection (day 1). A: FSE T1 weighted MRI Scan. B: FSE T2 weighted MRI scan. Arrows: localisation of the injected MnCl2 labelled cells in T1 (A) and T2 (B) weighted MRI. In T1 weighted MRI (A) the MnCl2 labelled cells were detected due to a strong signal enhancement.

Back to article page